/
JSPR
$0.42+$0.08 (+23.11%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.6M
28M shares
52-week range
$0.32 – $7.19
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
2.59%
Moderate
Price (6 mo)
Loading chart…
Change$-122.28
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.1M |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | −$1.1M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.6M | $15.9M | $25.4M | $34.6M | $51.8M | $55.8M | $60.5M |
| Operating income | −$4.7M | −$20.7M | −$36.8M | −$51.2M | −$68.9M | −$76.2M | −$80.5M |
| EBITDA | $0 | $0 | −$30.3M | −$36.7M | −$63.4M | −$69.9M | −$74.7M |
| Net income | −$5.0M | −$31.7M | −$30.6M | −$37.7M | −$64.5M | −$71.3M | −$75.8M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | 0.00 | -183.08 | -26.89 | -10.33 | -6.18 | -4.89 | -3.95 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-1.11 | $-1.11–$-1.11 | 2 |
| 2027 | $173800 | $-1.32 | $-2.12–$-0.49 | 3 |
| 2028 | $34M | $-0.84 | $-1.83–$-0.09 | 4 |
| 2029 | $17M | $-1.10 | $-1.10–$-1.10 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.44
Price
$0.42
Implied upside
+243%
Peer comparison
Jasper Therapeutics, Inc. Common Stock
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
www.jaspertherapeutics.com- Employees
- 22
- IPO / List date
- Sep 27, 2021
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds JSPR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 177,500 | $155.5K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-01-04 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded JSPR yet.
